C-reactive protein level and the incidence of eligibility for statin therapy

The multi-ethnic study of atherosclerosis

Devin M. Mann, Daichi Shimbo, Mary Cushman, Susan Lakoski, Philip Greenland, Roger S Blumenthal, Erin Donnelly Michos, Donald M. Lloyd-Jones, Paul Muntner

Research output: Contribution to journalArticle

Abstract

Background: Given the results of the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, statin initiation may be considered for individuals with elevated high-sensitivity C-reactive protein (hsCRP). However, if followed prospectively, many individuals with elevated CRP may become statin eligible, limiting the impact of elevated CRP as a treatment indication. This analysis estimates the proportion of people with elevated CRP that become statin eligible over time. Hypothesis: Most people with elevated CRP become statin eligible over a short period of time. Methods: We followed 2153 Multi-Ethnic Study of Atherosclerosis (MESA) participants free of cardiovascular disease and diabetes with low-density lipoprotein cholesterol

Original languageEnglish (US)
Pages (from-to)15-20
Number of pages6
JournalClinical Cardiology
Volume36
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
C-Reactive Protein
Atherosclerosis
Incidence
Therapeutics
Primary Prevention
LDL Cholesterol
Cardiovascular Diseases

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

C-reactive protein level and the incidence of eligibility for statin therapy : The multi-ethnic study of atherosclerosis. / Mann, Devin M.; Shimbo, Daichi; Cushman, Mary; Lakoski, Susan; Greenland, Philip; Blumenthal, Roger S; Michos, Erin Donnelly; Lloyd-Jones, Donald M.; Muntner, Paul.

In: Clinical Cardiology, Vol. 36, No. 1, 01.2013, p. 15-20.

Research output: Contribution to journalArticle

Mann, Devin M. ; Shimbo, Daichi ; Cushman, Mary ; Lakoski, Susan ; Greenland, Philip ; Blumenthal, Roger S ; Michos, Erin Donnelly ; Lloyd-Jones, Donald M. ; Muntner, Paul. / C-reactive protein level and the incidence of eligibility for statin therapy : The multi-ethnic study of atherosclerosis. In: Clinical Cardiology. 2013 ; Vol. 36, No. 1. pp. 15-20.
@article{80cfb95b17884bc1b3a94dbef395a7e5,
title = "C-reactive protein level and the incidence of eligibility for statin therapy: The multi-ethnic study of atherosclerosis",
abstract = "Background: Given the results of the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, statin initiation may be considered for individuals with elevated high-sensitivity C-reactive protein (hsCRP). However, if followed prospectively, many individuals with elevated CRP may become statin eligible, limiting the impact of elevated CRP as a treatment indication. This analysis estimates the proportion of people with elevated CRP that become statin eligible over time. Hypothesis: Most people with elevated CRP become statin eligible over a short period of time. Methods: We followed 2153 Multi-Ethnic Study of Atherosclerosis (MESA) participants free of cardiovascular disease and diabetes with low-density lipoprotein cholesterol",
author = "Mann, {Devin M.} and Daichi Shimbo and Mary Cushman and Susan Lakoski and Philip Greenland and Blumenthal, {Roger S} and Michos, {Erin Donnelly} and Lloyd-Jones, {Donald M.} and Paul Muntner",
year = "2013",
month = "1",
doi = "10.1002/clc.22046",
language = "English (US)",
volume = "36",
pages = "15--20",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - C-reactive protein level and the incidence of eligibility for statin therapy

T2 - The multi-ethnic study of atherosclerosis

AU - Mann, Devin M.

AU - Shimbo, Daichi

AU - Cushman, Mary

AU - Lakoski, Susan

AU - Greenland, Philip

AU - Blumenthal, Roger S

AU - Michos, Erin Donnelly

AU - Lloyd-Jones, Donald M.

AU - Muntner, Paul

PY - 2013/1

Y1 - 2013/1

N2 - Background: Given the results of the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, statin initiation may be considered for individuals with elevated high-sensitivity C-reactive protein (hsCRP). However, if followed prospectively, many individuals with elevated CRP may become statin eligible, limiting the impact of elevated CRP as a treatment indication. This analysis estimates the proportion of people with elevated CRP that become statin eligible over time. Hypothesis: Most people with elevated CRP become statin eligible over a short period of time. Methods: We followed 2153 Multi-Ethnic Study of Atherosclerosis (MESA) participants free of cardiovascular disease and diabetes with low-density lipoprotein cholesterol

AB - Background: Given the results of the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, statin initiation may be considered for individuals with elevated high-sensitivity C-reactive protein (hsCRP). However, if followed prospectively, many individuals with elevated CRP may become statin eligible, limiting the impact of elevated CRP as a treatment indication. This analysis estimates the proportion of people with elevated CRP that become statin eligible over time. Hypothesis: Most people with elevated CRP become statin eligible over a short period of time. Methods: We followed 2153 Multi-Ethnic Study of Atherosclerosis (MESA) participants free of cardiovascular disease and diabetes with low-density lipoprotein cholesterol

UR - http://www.scopus.com/inward/record.url?scp=84872289267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872289267&partnerID=8YFLogxK

U2 - 10.1002/clc.22046

DO - 10.1002/clc.22046

M3 - Article

VL - 36

SP - 15

EP - 20

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 1

ER -